Answers are grounded in this paper and cite their sources.
The two therapeutic approaches currently most advanced in clinical trials for Duchenne muscular dystrophy are antisense-mediated exon skipping and forced read-through of premature stop codons. Interestingly, these approaches target the gene product rather than the gene itself. This review will explain the rationale and current state of affairs of these approaches and will then discuss how these gene-derived therapies might also be applicable to other diseases.
No takes yet. Share an insight, caveat, or question.
Aartsma‐Rus et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: